Evangelos Liberopoulos

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Antonio J. Vallejo‐Vaz, Christophe Stevens, Alexander R.M. Lyons et al. · The Lancet · 2021 · 305 citations · Full text

Public Health, Endocrinology, Genetics +13

Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study

Vasilios G. Athyros, Dimitri P. Mikhailidis, Evangelos Liberopoulos et al. · Current Medical Research and Opinion · 2006 · 246 citations

Medicine, Internal Medicine, Pharmacotherapy +16

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Antonio J. Vallejo‐Vaz, Martina De Marco, Christophe Stevens et al. · Atherosclerosis · 2018 · 238 citations · Full text

Medicine, Cardiology, Genetics +11

“European Panel on Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses

Dimitri P. Mikhailidis, Moses Elisaf, Manfredi Rizzo et al. · Current Vascular Pharmacology · 2011 · 197 citations

Life Sciences, Biochemistry, Pharmacology +17